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Abstract
Background: We previously found a significant benefit of vitamin C supplementation in asthmatic children.
Purpose: To test whether the effect of vitamin C on asthma is heterogeneous over the participant population.
Methods: Egyptian asthmatic children between 7 and 10 years of age (n = 60) were included in the cross-over
trial. They were administered 0.2 grams per day of vitamin C and placebo for separate 6-week periods. The
variation in the vitamin C effect on two clinically relevant outcomes was analyzed: the childhood asthma control
test (C-ACT), which measures the severity of asthma symptoms (the scale ranges from 0 to 27 points, < 20 points
indicating unsatisfactory asthma control), and FEV1. We used linear modeling to examine the variation of the
vitamin C effect in the subgroups.
Results: The effect of vitamin C on the C-ACT was significantly modified by age and baseline C-ACT levels. In the
children aged 7.0-8.2 years with a baseline C-ACT of 18 to 19 points, vitamin C increased the C-ACT score by 4.2
points (95% CI: 3.3-5.3); whereas in the children aged 8.3-10 years who had a baseline C-ACT of 14 to 15 points,
vitamin C increased the C-ACT score by only 1.3 points (95% CI: 0.1-2.5). The effect of vitamin C on the FEV1 levels
was significantly modified by age and exposure to dampness. In the children aged 7.0-8.2 years with no exposure
to dampness, vitamin C increased the FEV1 level by 37% (95% CI: 34-40%), whereas in the children aged 8.3-10
years with exposure to dampness or mold in their bedroom more than one year prior to the study, vitamin C
increased the FEV1 level by only 21% (95% CI: 18-25%).
Conclusions: We found strong evidence that the effect of vitamin C on asthmatic children is heterogeneous.
Further research is needed to confirm our findings and identify the groups of children who would receive the
greatest benefit from vitamin C supplementation.
Keywords: age factors, ascorbic acid, asthma, child, effect modifiers, forced expiratory volume, obstructive lung dis-
eases, quality of life, controlled trials
Background
Proposals that vitamin C might be beneficial in the treat-
ment of asthma date back to the 1940s [1,2]. Nevertheless,
the role of vitamin C is still undefined. A study of Nigerian
asthmatics reported a 78% lower incidence of asthma
attacks in those administered vitamin C [3], whereas a
study of British asthmatics found no effect of vitamin C
on the symptoms or on the FEV1 levels [4]. Three trials
found that vitamin C reduces bronchoconstriction caused
by exercise in subjects who suffer from exercise-induced
bronchoconstriction (EIB) [5-7]. Although these three EIB
studies imply that vitamin C may have an effect on lung
function, the findings cannot be generalized to patients
with other variants of asthma.
There is no well-defined mechanism whereby vitamin
C may have an effect on asthma. Nevertheless, vitamin
C influences the production of various prostanoids in
lung tissues [8-11]. Indomethacin reverses the effect of
vitamin C on bronchoconstriction in guinea pigs [10-13]
and humans [14,15]. Thus, the effect of vitamin C on
airways might be, at least partly, mediated by influences * Correspondence: harri.hemila@helsinki.fi
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matic patients, the level of vitamin C is low in plasma
[1,16-18] and bronchoalveolar fluid [19]. Although such
a correlation does not imply a causal relationship, it
encourages research on vitamin C and asthma.
We have previously carried out a placebo-controlled
cross-over trial in which we examined the effect of vita-
min C, zinc, omega-3 fatty acids and their combination
in Egyptian asthmatic children [20]. Vitamin C signifi-
cantly decreased asthma symptoms and increased the
FEV1 levels [20]. We reasoned that the effect of vitamin
C might be greater in children who had low baseline
FEV1 levels and found that the effect was modified by
baseline FEV1 (unpublished). Therefore we decided to
c a r r yo u taf o r m a l l yp l a n n e ds u b g r o u pa n a l y s i so ft h e
data.
In this subgroup analysis, we planned to use two clini-
cally relevant outcomes: asthma symptoms as measured
by the childhood asthma control test (C-ACT) [21,22]
and pulmonary function as measured by FEV1.W e
planned to examine the effect of six baseline variables:
the C-ACT, the FEV1/FVC ratio, gender, paternal smok-
ing, exposure to dampness or mold in the bedroom, and
residential neighborhood. In this subgroup analysis, we
decided to use the baseline FEV1/FVC ratio instead of
the baseline FEV1 since the former adjusts for the varia-
tion in the size of lungs.
Methods
Participants and study design
The design and methods of the trial have been described
earlier [20]. In brief, 72 Egyptian children between 7 and
10 years of age, who were diagnosed of having moderate
persistent asthma (see [21] for the diagnostic criteria),
were included in the trial. Tw e l v ec h i l d r e nw e r el o s ta t
follow-up due to change in their residence. This study
reports the findings of the remaining 60 children (Table
1). The study was a randomized, double-blind, placebo-
controlled cross-over trial carried out over 38 weeks.
After a pre-trial assessment period of 2 weeks, the chil-
dren entered the study on their normal diet, after which
they entered five different 6-week therapeutic phases in
a random sequence, with observers, participants and
families blinded to the treatment: placebo, vitamin C,
zinc, omega-3 fatty acids, and a combination of the
three. Each phase was followed by a 2-week washout
period before the next phase. Thus, by the end of the
study, all the children had been exposed to the five
treatment phases (placebo included) but in different
sequences. In the vitamin C phase, the children were
administered 0.2 g per day of ascorbic acid in capsules
that appeared identical to the placebo capsules. The trial
was approved by the Department Council and the
Faculty Ethical committee. The current subgroup
analysis is restricted to the comparison of the vitamin C
and placebo phases.
Background data and outcomes
At the beginning of the study and at the end of each
treatment phase, the severity of asthma was assessed
using the childhood asthma control test (C-ACT), and a
pulmonary function test was performed. The C-ACT is
a questionnaire for asthmatic children and their parents
for identifying children aged 4-11 years whose asthma is
inadequately controlled: the scale ranges from 0 to 27
points, < 20 points indicating unsatisfactory asthma con-
trol [22,23]. Spirometry was performed in a sitting posi-
tion by all the children (spirometer: Morgan TLC Test
Mk 11, Morgan Scientific, Haverhill, MA, USA). Partici-
pants performed three acceptable FVC maneuvers, and
the highest FEV1 value was recorded.
Information on the presence of dampness or mold in
the bedroom was obtained with a questionnaire based
on four items confirmed by parent reporting [24]: 1)
mold odor (n = 3), 2) visible mold (n = 29), 3) moisture
(n = 19), 4) water damage (n = 21). Dampness or mold
in the bedroom was defined as one or more positive
r e s p o n s e s .T h eq u e s t i o na b o u tt h et i m eo fe x p o s u r et o
dampness had two alternatives: 1) “during the past 12
months” and 2) “only earlier” (i.e. more than one year
Table 1 Demographic data of the asthma patients
Number of children who started the trial 76
Number of children who completed the trial 60
Mean (SD)
Age (yr) 8.4 (1.0)
Weight (kg) 32 (18)
Height (cm) 124 (21)
BMI (kg/m
2) 17.2 (1.3)
No. of
children
Boys/Girls 38/22
Urban/Rural 34/26
Associated nasal allergy 12
Asthma medications:
Long acting b2-agonist alone 0
Moderate daily dose inhaled corticosteroid 16
Long acting b2-agonist + inhaled corticosteroid 20
b2-agonist + inhaled corticosteroid + intermittent
short acting b2-agonist
18
b2-agonist + inhaled corticosteroid + sodium
cromoglycate
6
Allergy medications:
Antihistamine 24
Intermittent nasal decongestant 24
Nasal corticosteroid 16
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and earlier exposure alternatives.
As the outcome for the FEV1 change, we calculated
the percentage increment in the FEV1 value between the
end of the vitamin C and placebo phases. As the pri-
mary outcome for the C-ACT change, we calculated the
arithmetic difference in the C-ACT between the end of
the vitamin C and the placebo phases. Since we found
that the vitamin C effect on the C-ACT was greater on
participants with high baseline C-ACT values (Table 2),
in Table 3 we also calculated the percentage increment
in the C-ACT scores as a secondary outcome. In the
normal plot, the distribution of the changes in the C-
ACT and FEV1 were quite close to the normal
distribution.
Statistical methods
To minimize the multiple comparison problem asso-
ciated with subgroup analysis, we wrote a protocol in
which we planned this study (Additional file 1). We
decided to focus on two clinically relevant primary out-
comes, the C-ACT difference and the FEV1 ratio
Table 2 Effect of vitamin C on the symptoms of asthmatic children
Subgroup No. of Children C-ACT
(mean)
Difference in C-ACT Test for interaction (P)
Placebo Vitamin C Estimate 95% CI
All 60 16.57 19.60 3.03 2.53-3.54
C-ACT at baseline
13-15 30 15.8 18.1 2.3 1.7-3.0 0.004
a)
16-19 30 17.3 21.1 3.7 3.0-4.5
FEV1/FVC (%)
< 59 28 16.4 19.3 2.9 2.3-3.6 0.7
a)
≥59 32 16.8 19.9 3.1 2.3-3.9
FEV1 at baseline (L/s)
< 1.1 29 16.7 20.3 3.6 3.0-4.3 0.013
a)
≥1.1 31 16.5 18.9 2.5 1.7-3.2
Age (yr)
7.0-8.2 30 16.6 20.3 3.7 3.1-4.3 0.004
a)
8.3-10 30 16.5 18.9 2.3 1.5-3.1
Weight (kg)
23-28 29 16.6 19.3 2.7 1.9-3.5 0.2
a)
29-37 31 16.6 19.9 3.3 2.7-4.0
Gender
Girl 22 16.5 19.5 3.0 2.2-3.9 1.0
Boy 38 16.6 19.6 3.0 2.3-3.7
Dampness exposure
Never 25 16.8 19.2 2.4 1.4-3.4 0.1
b)
During past 1 yr 20 16.3 19.7 3.4 2.6-4.2
Earlier 14 16.5 20.1 3.6 2.8-4.4
Smoking by the father
Never 21 16.5 19.0 2.5 1.6-3.5 0.4
c)
Current 22 16.8 19.8 3.0 2.2-3.9
Ex-smoker 17 16.4 20.0 3.6 2.7-4.6
Residential area
Urban 34 16.5 19.5 3.0 2.4-3.7 1.0
Rural 26 16.7 19.7 3.0 2.2-3.9
a) The test of interaction was calculated by using dichotomized variables for the C-ACT, FEV1/FVC ratio, FEV1, age, and weight (cut points at the medians). The
test of interaction by using the continuous variables gives P = 0.0002 for the baseline C-ACT and P = 0.005 for age.
b) The test of interaction is restricted to the “Never” and “During past 1 yr” subgroups. One child who was exposed to dampness both “During past 1 yr” and
“Earlier” is excluded from this subgroup comparison.
c) The test of interaction is restricted to the “Never” and “Current” subgroups.
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vitamin C effect by six variables: the baseline C-ACT,
the baseline FEV1/FVC ratio, gender, paternal smoking,
dampness or mold in the bedroom, and residential
neighborhood (urban/rural) (see details in the Addi-
tional file 1). This series of subgroup analyses were
motivated by our finding that the baseline FEV1 modi-
fied the vitamin C effect on the FEV1 level. In the sub-
group analysis protocol, we considered that the baseline
FEV1/FVC ratio would be a better variable for subgroup
division as it adjusts for the size of the lungs. Unexpect-
edly, we did not find a modification of the vitamin C
effect by the baseline FEV1/FVC ratio. The baseline
FEV1 has a close correlation with age (r = 0.95), whereas
the correlation between the baseline FEV1 and the base-
line FEV1/FVC ratio is weak (r = 0.12). Therefore, we
added FEV1 and age to the tables to examine whether
the divergence between the baseline FEV1/FVC ratio
and the FEV1 levels might be explained by age. Further-
more, we also added weight to the tables to test whether
it is the young age per se or the low weight (higher dose
per weight unit) that better explains the greater effect
on the younger children.
We divided the children into subgroups by C-ACT,
FEV1/FVC ratio, FEV1,a g e ,a n dw e i g h tw i t ht h ec u t
points at the medians. Effect modification by paternal
smoking was tested by comparing never smokers with
current smokers, so that ex-smokers were excluded.
Similarly, effect modification by dampness or mold in
the bedroom was tested by comparing never exposed to
those children who were only recently exposed (< 1
year), so that those exposed to dampness in their earlier
childhood (> 1 year prior to the study) were excluded.
The excluded groups are shown in the tables, but they
were not included in the test of interaction.
We tested the interaction between vitamin C effect
and the subgroup variables by using linear models. To
test whether the vitamin C supplementation effect is dif-
ferent between the subgroups, we first added a uniform
vitamin C effect to all the children. Then we added an
interaction term between vitamin C and the subgroup
variable. The improvement of the linear model fit was
thereafter calculated from the change in -2 × log (likeli-
hood), which follows the c
2 distribution with degrees of
freedom defined by the number of interaction terms.
Although the C-ACT difference was close to the normal
distribution, the values were integers in a range of -2 to +6
points. Therefore, we confirmed the most essential sub-
group differences in Table 2 by a nonparametric test. The
Wilcoxon test gave similar P-values for the interaction test
between vitamin C effect on C-ACT and the dichotomous
baseline C-ACT (P = 0.010) and age (P = 0.005), consis-
tent with the t-test results in Table 2. The linear models,
the t-test-based 95% confidence intervals (95% CI) of the
effects, and the Wilcoxon tests were calculated using the
R-package [25]. Two-tailed P-values are shown.
Results
The essential characteristics of the 60 children are
described in Table 1. On average, vitamin C
Table 3 Vitamin C and asthma symptoms: effect modification by age and baseline asthma severity
Age (yr) C-ACT at baseline No of. Children Symptoms (C-ACT)
Mean
Arithmetic increase in C-ACT
a) Percentage increment in C-ACT
b)
Placebo Vitamin C Mean 95% CI Mean 95% CI
7.0-8.2 18-19 12 17.6 21.8 4.2 3.3-5.2 24% 18-31%
16-17 10 16.3 20.0 3.7 2.4-5.0 23% 15-32%
13-15 8 15.5 18.5 3.0 2.4-3.6 19% 16-23%
8.3-10 18-19 8 17.2 21.0 3.7 1.6-5.8 23% 9-36%
16-17 10 16.8 19.2 2.4 1.5-3.3 14% 9-20%
14-15 12 15.8 17.2 1.3 0.1-2.5 9% 1-17%
a) Arithmetic increase in the C-ACT. When age and baseline C-ACT as continuous variables were included in the linear model explaining the effect of vitamin C,
the model was improved by c
2(2 df) = 19.1, P = 0.00007 (model parameters are shown in Table 4). There was no second order interaction between the baseline
C-ACT and age in their modification of the vitamin C effect (c
2(1 df) = 2.1, P = 0.2).
b) Percentage increment in the C-ACT. When age and baseline C-ACT as continuous variables were included in the linear model explaining the effect of vitamin
C, the model was improved by c
2(2 df) = 14.0, P = 0.0009. There was no second order interaction between the baseline C-ACT and age in their modification of
the vitamin C effect (c
2(1 df) = 2.6, P = 0.1).
Table 4 Effect of vitamin C on the C-ACT level:
parameters estimating the effect modification by age
and baseline C-ACT
Variable Effect of vitamin C on the
C-ACT level
a)
Age 7.0 yr, baseline C-ACT 13 points +2.12 (SE 0.65)
Age (per year over 7.0 yr) -0.52 (SE 0.22)
Baseline C-ACT (per point over 13) +0.46 (SE 0.13)
a) These parameters are from the linear model for the arithmetic increase in
C-ACT described in the footnote of Table 3. SE, standard error. This model
predicts, for example, that a 9-yr old child with baseline C-ACT of 19 would
have 3.84 point increase in C-ACT by vitamin C administration which is close
to that observed (3.7) for the older children with baseline C-ACT 18 or 19 in
Table 3.
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C-ACT, by 3.0 points (Table 2). This effect was modi-
fied by the baseline C-ACT so that vitamin C was more
effective in those children who had less severe asthma
symptoms. The evidence of effect modification was
stronger when the baseline C-ACT was included in the
statistical model as a continuous variable (P = 0.0002)
than as a dichotomous variable (P = 0.004), which indi-
cates that the effect modification was better captured by
the continuous baseline C-ACT.
The baseline FEV1/FVC ratio did not modify the effect
of vitamin C on the C-ACT (Table 2). This was incon-
sistent with the modification caused by the baseline
FEV1, which gave us the motivation for this subgroup
analysis. Because of this discrepancy, we considered that
the modification by the baseline FEV1 might be
explained by the close correlation between age and
FEV1. Since age significantly modified the vitamin C
effect, whereas baseline FEV1/FVC ratio did not, we
concluded that the modification by the baseline FEV1
was simply reflecting the effect of age on FEV1 (Table
2). There was no substantial difference between includ-
ing age as a dichotomous or a continuous variable in
the statistical model. Gender and residential area did
not modify the effect of vitamin C. There was also no
significant difference between the children who were
currently or had never been exposed to dampness in the
bedroom, or between the children whose fathers were
current smokers or had never smoked (Table 2).
Given that the baseline C-ACT and age modified the
effect of vitamin C, we analyzed the combined effect of
these two variables (Tables 3 and 4). When both of
these variables were simultaneously included in the lin-
ear model, it was substantially improved (P = 0.0001), so
that the proportion of variance in the vitamin C effect
explained by these two variables was 27% (R
2 =0 . 2 7 ) .
There was no second order interaction between these
two variables in their influence on the vitamin C effect
(Table 3). The greatest effect of vitamin C on the C-
ACT was seen in the younger children who had mild
asthma symptoms (4.2 point increase), whereas the
s m a l l e s te f f e c tw a ss e e ni nt h eo l d e rc h i l d r e nw h oh a d
severe asthma symptoms (1.3 point increase). The esti-
mated influence of the baseline C-ACT and age on the
vitamin C effect is shown in Table 4.
In our analysis of the C-ACT change, we used the
absolute difference as the primary outcome. However, as
we found a greater effect in those children who had a
high initial C-ACT score, we also analyzed Table 3 het-
erogeneity by using the percentage increment in the C-
ACT score. With this secondary outcome, we also
found strong evidence of heterogeneity in vitamin C
effect between the children (P = 0.001).
On average, vitamin C increased the FEV1 level by
29% (Table 5). This effect was modified by age, and con-
tinuous age was better than dichotomous age in captur-
ing the interaction (Table 5). The effect of vitamin C on
FEV1 was also modified by dampness in the bedroom.
Our test of interaction was restricted to the children
who were currently or had never been exposed to
dampness in the bedroom. However, the effect of vita-
min C was smallest in the children who were exposed
to dampness in their earlier childhood. Other tested
baseline variables did not modify the effect of vitamin C
(Table 5).
When both age and exposure to dampness were
included in the same statistical model to explain FEV1
changes, the model was significantly improved (P = 10
-10)
(Tables 6 and 7). The proportion of variance in the vita-
min C effect explained by the two variables was 58%
(R
2 = 0.58). There was no second order interaction
between age and exposure to dampness in their influence
on the vitamin C effect. The greatest effect of vitamin C
on FEV1 was seen in the younger children who had never
been exposed to dampness or mold in their bedroom
(37% increase in FEV1), whereas the smallest effect was
seen in the older children who had been exposed to
dampness more than one year prior to the study (21%
increase in FEV1)(Table 6). The estimated influence of
age and exposure to dampness on the vitamin C effect is
shown in Table 7.
S i n c ee x p o s u r et od a m p n ess was composed of four
indicator items, we explored whether there might be dif-
ferences between the indicators; mold odor was reported
only by 3 children, and it was excluded from this com-
parison. Within the accuracy of the confidence intervals,
there were no differences between the three other indi-
cators in the modification of the vitamin C effect on the
FEV1 level (data not shown).
Discussion
We found that age modified the effect of vitamin C on
asthma symptoms (C-ACT) and on the FEV1 level in
this group of Egyptian children. In addition, the vitamin
C effect on asthma symptoms was modified by baseline
C-ACT, and the vitamin C effect on the FEV1 level was
modified by exposure to dampness in the bedroom.
Previously, an age-dependent variation in the vitamin
Ce f f e c to nc o m m o nc o l dd u r a t i o nw a sn o t e d ,b u ti t
was not evident whether the greater effect on children
than on adults was caused by age per se o rb yah i g h e r
dose per weight unit since children weigh less [26,27].
In the current study, we found a greater vitamin C effect
on younger children, and this was not explained by
weight differences (Tables 2 and 5). Still, it is possible
that the heterogeneity over age might be caused by
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possibility does not challenge the strong evidence indi-
cating that substantial heterogeneity exists across this
group of children.
When planning this subgroup analysis, we reasoned that
the effect of vitamin C might be greater in children who
had the lowest baseline C-ACT level and FEV1/FVC ratio,
and in children who had been exposed to dampness
(Additional file 1). However, we found the opposite direc-
tion for the modification by C-ACT, namely the effect
of vitamin C was greater in those who had a high baseline
C-ACT level. We also found that the relation between the
baseline FEV1 and the vitamin C effect, which gave us the
motivation for this study, was explained by age and not by
the baseline FEV1/FVC ratio. In addition, contrary to our
expectation, exposure to dampness in the bedroom was
associated with a decreased effect of vitamin C. Thus,
although the baseline C-ACT and dampness modified the
vitamin C effect, the modification was in a direction oppo-
site to our expectation.
Gender differences have been found in the vitamin C
effects on the common cold [28-30], but in this study
Table 5 Effect of vitamin C on the FEV1 levels of asthmatic children
Subgroup No. of Children FEV1
Mean (L/s)
Change in FEV1 Test for interaction (P)
Placebo Vitamin C Estimate 95% CI
All 60 1.125 1.446 28.9% 27.3-30.4%
C-ACT at baseline
13-15 30 1.16 1.48 27.5% 25.4-29.6% 0.07
a)
16-19 30 1.09 1.41 30.3% 28.0-32.6%
FEV1/FVC (%)
< 59 28 1.11 1.43 29.4% 27.0-31.9% 0.5
a)
≥59 32 1.14 1.46 28.4% 26.3-30.5%
FEV1 at baseline (L/s)
< 1.1 29 1.00 1.31 31.1% 28.6-33.6% 0.004
a)
≥1.1 31 1.24 1.58 26.8% 25.1-28.5%
Age (yr)
7.0-8.2 30 1.00 1.31 31.1% 28.7-33.5% 0.003
a)
8.3-10 30 1.25 1.58 26.7% 24.9-28.4%
Weight (kg)
23-28 29 1.12 1.44 29.7% 27.1-32.3% 0.3
a)
29-37 31 1.13 1.45 28.1% 26.2-30.0%
Gender
Girl 22 1.07 1.37 28.6% 25.6-31.6% 0.8
Boy 38 1.16 1.49 29.0% 27.2-30.9%
Dampness exposure
Never 25 1.16 1.53 32.4% 30.2-34.6% 0.001
b)
During past 1 yr 20 1.11 1.42 27.6% 25.9-29.4%
Earlier 14 1.07 1.34 25.0% 21.2-28.8%
Smoking by the father
Never 21 1.17 1.52 30.1% 28.0-32.2% 0.4
c)
Current 22 1.08 1.38 28.5% 25.3-31.7%
Ex-smoker 17 1.12 1.43 27.9% 24.9-30.9%
Residential area
Urban 34 1.09 1.40 29.2% 27.2-31.3% 0.6
Rural 26 1.17 1.50 28.4% 25.8-31.0%
a) The test of interaction was calculated by using dichotomized variables for the C-ACT, FEV1/FVC ratio, FEV1, age, and weight (cut points at the medians). The
test of interaction by using the continuous variables gives P = 0.2 for the baseline C-ACT and P = 0.001 for age.
b) The test of interaction is restricted to the “Never” and “During past 1 yr” subgroups. One child who was exposed to dampness both “During past 1 yr” and
“Earlier” is excluded from this subgroup comparison.
c) The test of interaction is restricted to the “Never” and “Current” subgroups.
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Urban and rural neighborhoods differ in the type of out-
door air pollution, and passive smoking causes irritation
of the airways, but we found no modification of the vita-
min C effect by residential neighborhood or paternal
smoking.
We found substantial heterogeneity in the effect of
vitamin C, over two-fold variation in the effect between
the extremes of the subgroups in Tables 3 and 6. Thus,
the effect of vitamin C on asthma seems to be context
dependent. This heterogeneity in the vitamin C effect
seems important since it indicates that no universal
effect should be sought. Instead, the characteristics and
living conditions of asthma patients who would get the
greatest benefit from vitamin C should be targeted.
The heterogeneity we found within these children also
has implications for the interpretation of previous stu-
dies. Two randomized, double-blind, placebo-controlled
trials found divergent effects of vitamin C in asthmatic
patients. In Nigeria, Anah et al. found a 78% reduction
in the incidence of asthma attacks in 15 to 46 year-old
patients administered 1 g/day of vitamin C [3]. In the
UK, Fogarty et al. did not find any effect of 1 g/day of
vitamin C on asthma symptoms or FEV1 levels in 18 to
64 year-old asthmatics [4]. Since differences in nutrition
or lifestyle, or other differences between the participants
of the two trials may explain the divergent findings, the
newer trial [4] should not be considered a refutation of
the older trial [3].
Asthma is a collection of different phenotypes, rather
than a single disease [31,32]. These phenotypes are cate-
gorized under the broad umbrella of “asthma” because
they meet the criteria for the clinical diagnosis of the
disease. Allergic sensitization that triggers asthma may
be the largest phenotype. There is also evidence that
molds are an important environmental trigger for
asthma exacerbations, and the effects of molds are pos-
sibly caused, at least partly, by their mycotoxins
[24,33-35]. Furthermore, the mechanisms behind EIB
seem to be different from those of ordinary asthma [36].
Given the variety of mechanisms causing asthma-type
symptoms, it seems plausible that vitamin C has differ-
ent effects on different types of asthma. Thus, although
three trials consistently found a benefit of vitamin C
against EIB [5-7], those studies cannot be extrapolated
to other types of asthma. In this study, we found that
the effect of vitamin C on the FEV1 level of asthmatic
children was significantly modified by exposure to
dampness or mold in the bedroom.
A number of subgroup comparisons were carried out
in our study, and therefore the multiple comparison
problem might be of concern. However, the particularly
low P-values seen in Tables 2 and 5 are not easily
explained by the 18 subgroup comparisons in these two
tables. Furthermore, the proportion of variance in the
vitamin C effect explained by the statistical models (R
2)
in Tables 3 and 6 is high. Therefore, we do not consider
that the differences identified might be easily explained
by multiple testing.
Our study was randomized, double blind and placebo
controlled. Nevertheless, our study has various
Table 6 Vitamin C and FEV1: effect modification by age and exposure to dampness
Age (yr) Exposure to dampness in the bedroom No of. Children
a) FEV1 (L/s) Percentage increment in FEV1
b)
Placebo Vitamin C Mean 95% CI
7.0-8.2 Never 10 0.98 1.34 37.0% 33.9-40.2%
During past 1 yr 11 1.04 1.34 29.0% 27.4-30.6%
Earlier 9 0.99 1.25 27.1% 21.5-32.6%
8.3-10 Never 15 1.28 1.66 29.3% 27.6-31.1%
During past 1 yr 9 1.21 1.52 25.9% 22.5-29.4%
Earlier 5 1.23 1.49 21.3% 18.0-24.5%
a) Since the goal of this table is to compare the effect of “During past 1 yr” and “Earlier” exposure to dampness, one child who had both modes of exposure was
excluded (age 8.4 yr), making the number of children in this analysis 59.
b) When age as a continuous variable and the three categories of dampness were included in the linear model explaining the effect of vitamin C on the FEV1
increase, the model was improved by c
2(3 df) = 51.8, P = 10
-10 (model parameters are shown in Table 7). There was no second order interaction between age
and dampness in their modification of the vitamin C effect (c
2(2 df) = 2.3, P = 0.3).
Table 7 Effect of vitamin C on the FEV1 level: parameters
estimating the effect modification by age and exposure
to dampness
Variable Effect of vitamin C on the FEV1
level
a)
Age 7.0 yr, no exposure to
dampness
+37.9% (SE 1.2%)
Age (per year over 7.0 yr) -3.37% (SE 0.52%)
Exposure to dampness during
past 1 yr
-5.8% (SE 1.2%)
Exposure to dampness earlier -9.6% (SE 1.4%)
a) These parameters are from the linear model described in the footnote of
Table 6. SE, standard error. This model predicts, for example, that a 9-yr old
child with exposure to dampness earlier than 1 year before the study would
have 21.5% increase in FEV1 by vitamin C administration which is close to that
observed (21.3%) for the older children with early dampness exposure in
Table 6.
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Page 7 of 9limitations. Our study subjects were Egyptian children,
and it is not clear whether the same modifying factors
might apply to children in industrialized countries or in
other developing countries or to adults. There may have
been inaccuracy in the measurement of mold exposure;
however, nondifferential misclassification would move
the estimate of interaction effect towards the null value
(of no interaction) and cannot generate an artificial dif-
ference between the exposed and unexposed [37]. The
duration of vitamin C administration was only 6 weeks,
and it is not evident whether the observed effect lasts
substantially longer. In a cross-over study, the carry-
over effect from the intervention phase to the placebo
p h a s ec o u l dr e d u c et h ed i f f e r e n c eb e t w e e nt h et w o
phases, but cannot bias in the direction of greater effect.
The dose of vitamin C was rather low, 0.2 g/day, and
our study does not give any information about dose
dependency: whether higher doses might cause a greater
effect or whether similar effects might be caused by
even lower doses. Such issues should be considered in
future studies on vitamin C and childhood asthma.
Conclusions
We found strong evidence that the effect of vitamin C
on asthmatic Egyptian children is heterogeneous. The
highest effects observed, the 37% increase in the FEV1
level and the 4.2 point increase in the C-ACT level, are
substantial and clinically important. It would seem
important to carry out further research to confirm our
findings and more accurately identify the groups of chil-
dren who would receive the greatest benefit from vita-
min C supplementation.
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